MONASH IVF GROUP LIMITED (MVF)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MVF - MONASH IVF GROUP LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 1.99
Index: ALL-ORDS

Monash IVF is an Australian provider of IVF, Ultrasound and genetic testing services throughout Australia and Asia. The company has been listed since 2014.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.335

06 Dec
2023

0.025

OPEN

$1.31

1.91%

HIGH

$1.34

455,983

LOW

$1.31

TARGET
$1.38 3.4% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . CAJ . DOC . EBO . HLA . HLS . M7T . MDR . MPL . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
MVF: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx 5.6 7.3 xxx
DPS (cps) xxx 4.4 5.0 xxx
EPS Growth xxx 18.6% 29.8% xxx
DPS Growth xxx 0.0% 13.6% xxx
PE Ratio xxx N/A 18.6 xxx
Dividend Yield xxx N/A 3.7% xxx
Div Pay Ratio(%) xxx 78.6% 68.8% xxx

Dividend yield today if purchased 3 years ago: 6.11%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 3.26

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 07/09 - ex-div 2.2c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx5.6
DPS All xxxxxxxxxxxxxxx4.4
Sales/Revenue xxxxxxxxxxxxxxx213.6 M
Book Value Per Share xxxxxxxxxxxxxxx70.1
Net Operating Cash Flow xxxxxxxxxxxxxxx38.0 M
Net Profit Margin xxxxxxxxxxxxxxx10.22 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx8.07 %
Return on Invested Capital xxxxxxxxxxxxxxx6.20 %
Return on Assets xxxxxxxxxxxxxxx5.40 %
Return on Equity xxxxxxxxxxxxxxx8.07 %
Return on Total Capital xxxxxxxxxxxxxxx9.70 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-7.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx6 M
Long Term Debt xxxxxxxxxxxxxxx94 M
Total Debt xxxxxxxxxxxxxxx100 M
Goodwill - Gross xxxxxxxxxxxxxxx255 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx8 M
Price To Book Value xxxxxxxxxxxxxxx1.63

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx27.8 M
Capex % of Sales xxxxxxxxxxxxxxx13.01 %
Cost of Goods Sold xxxxxxxxxxxxxxx150 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx28 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx2 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

23/08/2023

1

Add

$1.29

-3.37%

FY23 underlying profit of $25.5m for Monash IVF was in line with guidance with a stable earnings (EBITDA) margin of 25% as price rises offset cost pressures, explains Morgans. It's felt FY24 will be another strong year of growth.

The broker anticipates this growth from a range of sources including contribution of acquisitions, a rebound in ultrasound procedures  and growth in South East Asia. Market share gains are also expected from organic growth and recruitment of new specialists.

The Add rating and $1.29 target are retained.

FORECAST
Morgans forecasts a full year FY24 dividend of 5.00 cents and EPS of 7.20 cents.
Morgans forecasts a full year FY25 dividend of 5.00 cents and EPS of 7.70 cents.

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

MVF STOCK CHART

FNArena News on MVF

1
Australian Broker Call *Extra* Edition – Nov 06, 2023

Nov 06 2023 - Daily Market Reports
2
Rudi’s Comprehensive August 2023 Review

Sep 21 2023 - Feature Stories
3
Rudi’s View: Navigating The Post-August Complexities

Sep 20 2023 - Rudi's View
4
Australian Broker Call *Extra* Edition – Aug 30, 2023

Aug 30 2023 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Aug 25, 2023

Aug 25 2023 - Daily Market Reports

Latest Healthcare services News

1
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
2
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
3
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
4
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
5
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
6
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
7
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps
8
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia
9
Ramsay Stakes Future on Mental Health

Dec 20 2021 - Australia
10
Ramsay Health Care: Finally A Break-Out

Nov 09 2021 - Technicals